No retraction, correction or concern found when last checked on Nov 5, 2026.
Inhibition of SARS‐CoV 3C‐like Protease Activity by Theaflavin‐3,3′‐digallate (TF3)
Chia-Nan Chen, Coney P. C. Lin, Kuo-Kuei Huang and 4 more (opens in a new tab)
Evidence-Based Complementary and Alternative Medicine · 2005 · CC BY
doi:10.1093/ecam/neh081 (opens in a new tab)
Abstract
SARS‐CoV is the causative agent of severe acute respiratory syndrome (SARS). The virally encoded 3C‐like protease (3CLPro) has been presumed critical for the viral replication of SARS‐CoV in infected host cells. In this study, we screened a natural product library consisting of 720 compounds for inhibitory activity against 3CLPro. Two compounds in the library were found to be inhibitive: tannic acid (IC50 = 3 µM) and 3‐isotheaflavin‐3‐gallate (TF2B) (IC50 = 7 µM). These two compounds belong to a group of natural polyphenols found in tea. We further investigated the 3CLPro‐inhibitory activity of extracts from several different types of teas, including green tea, oolong tea, Puer tea and black tea. Our results indicated that extracts from Puer and black tea were more potent than that from green or oolong teas in their inhibitory activities against 3CLPro. Several other known compositions in teas were also evaluated for their activities in inhibiting 3CLPro. We found that caffeine, (—)‐epigallocatechin gallte (EGCg), epicatechin (EC), theophylline (TP), catechin (C), epicatechin gallate (ECg) and epigallocatechin (EGC) did not inhibit 3CLPro activity. Only theaflavin‐3,3′‐digallate (TF3) was found to be a 3CLPro inhibitor. This study has resulted in the identification of new compounds that are effective 3CLPro inhibitors.
References 21
- 1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1056/nejmoa030781 (opens in a new tab)
- 2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1056/nejmoa030747 (opens in a new tab)
- 3.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1126/science.300.5618.413 (opens in a new tab)
- 4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1126/science.300.5620.715 (opens in a new tab)
- 5.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1056/nejmp030072 (opens in a new tab)
- 6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1126/science.1086418 (opens in a new tab)
- 7.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1099/0022-1317-83-3-581 (opens in a new tab)
- 8.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1126/science.1085953 (opens in a new tab)
- 9.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1126/science.1085952 (opens in a new tab)
- 10.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1128/jvi.72.2.910-918.1998 (opens in a new tab)
- 11.
- 12.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1128/jvi.73.1.177-185.1999 (opens in a new tab)
- 13.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 14.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 15.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 16.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1093/jn/131.9.2248 (opens in a new tab)
- 17.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1126/science.1085658 (opens in a new tab)
- 18.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1021/jf034634b (opens in a new tab)
- 19.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 20.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1016/s0378-1135(98)00242-9 (opens in a new tab)
- 21.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1016/j.gastro.2003.08.001 (opens in a new tab)
Cited by papers we hold 3
- The SARS‐CoV‐2 main protease (M pro ): Structure, function, and emerging therapies for COVID‐19 · 2022No notice
- Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2 · 2020Not checked
- Tea Polyphenols EGCG and Theaflavin Inhibit the Activity of SARS‐CoV‐2 3CL‐Protease In Vitro · 2020No notice
Questions about this paper
We email you if it is retracted, withdrawn, corrected or flagged.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.